25.42
price up icon0.12%   0.03
after-market Handel nachbörslich: 25.48 0.06 +0.24%
loading
Schlusskurs vom Vortag:
$25.39
Offen:
$24.688
24-Stunden-Volumen:
2.03M
Relative Volume:
0.80
Marktkapitalisierung:
$2.57B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-14.04
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
+1.15%
1M Leistung:
+23.40%
6M Leistung:
+49.53%
1J Leistung:
-4.40%
1-Tages-Spanne:
Value
$23.53
$26.04
1-Wochen-Bereich:
Value
$23.53
$28.75
52-Wochen-Spanne:
Value
$13.53
$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Firmenname
Beam Therapeutics Inc
Name
Telefon
857-327-8775
Name
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Mitarbeiter
509
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
BEAM's Discussions on Twitter

Vergleichen Sie BEAM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BEAM
Beam Therapeutics Inc
25.42 2.66B 352.57M -143.01M -153.40M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.22 104.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.36 60.95B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.60 59.11B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.95 49.23B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.94 35.92B 4.56B -176.77M 225.30M -1.7177

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-09 Eingeleitet Jefferies Buy
2025-03-28 Hochstufung BofA Securities Neutral → Buy
2025-03-10 Hochstufung Scotiabank Sector Perform → Sector Outperform
2025-01-29 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-11-06 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-07-23 Eingeleitet H.C. Wainwright Buy
2024-01-29 Hochstufung JP Morgan Neutral → Overweight
2023-12-15 Herabstufung BofA Securities Buy → Neutral
2023-12-08 Herabstufung Jefferies Buy → Hold
2023-10-20 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-10-20 Herabstufung Leerink Partners Outperform → Market Perform
2023-03-21 Eingeleitet Bernstein Mkt Perform
2023-02-01 Eingeleitet Cantor Fitzgerald Overweight
2022-12-20 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-12-13 Eingeleitet Citigroup Buy
2022-06-17 Eingeleitet BMO Capital Markets Market Perform
2022-04-28 Eingeleitet Credit Suisse Neutral
2022-01-05 Eingeleitet Guggenheim Buy
2021-10-19 Eingeleitet SVB Leerink Outperform
2021-09-24 Fortgesetzt Stifel Buy
2021-09-10 Eingeleitet BofA Securities Buy
2021-05-11 Eingeleitet Redburn Buy
2021-05-04 Eingeleitet RBC Capital Mkts Sector Perform
2021-03-01 Herabstufung Barclays Overweight → Equal Weight
2021-02-16 Eingeleitet Wells Fargo Overweight
2021-01-29 Herabstufung JP Morgan Overweight → Neutral
2021-01-06 Eingeleitet Stifel Hold
2020-08-05 Eingeleitet William Blair Outperform
2020-03-02 Eingeleitet Barclays Overweight
2020-03-02 Eingeleitet JP Morgan Overweight
2020-03-02 Eingeleitet Jefferies Buy
2020-03-02 Eingeleitet Wedbush Outperform
Alle ansehen

Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten

pulisher
05:39 AM

What the charts say about Beam Therapeutics Inc. todayMarket Sentiment Report & Real-Time Buy Signal Notifications - newser.com

05:39 AM
pulisher
05:35 AM

Why Beam Therapeutics Inc. stock is favored by pension funds2025 Market WrapUp & Low Drawdown Investment Ideas - newser.com

05:35 AM
pulisher
02:42 AM

What analyst consensus says on Beam Therapeutics Inc. stockChart Signals & Free Accurate Trade Setup Notifications - newser.com

02:42 AM
pulisher
01:53 AM

Should you wait for a breakout in Beam Therapeutics Inc.Earnings Overview Report & Growth Focused Entry Point Reports - newser.com

01:53 AM
pulisher
Oct 13, 2025

Sickle Cell Disease Pipeline Insights Report 2025: DelveInsight Highlights Cutting-Edge Treatments and Clinical Progress - The Globe and Mail

Oct 13, 2025
pulisher
Oct 13, 2025

Technical analysis overview for Beam Therapeutics Inc. stockM&A Rumor & High Conviction Trade Alerts - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Visualizing Beam Therapeutics Inc. stock with heatmapsJuly 2025 Review & Technical Buy Zone Confirmation - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

Beam Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Oct 12, 2025
pulisher
Oct 11, 2025

Beam Therapeutics (BEAM): Assessing Valuation After Fresh Buy Ratings, Clinical Updates, and Institutional Moves - Yahoo Finance

Oct 11, 2025
pulisher
Oct 11, 2025

Jim Cramer on Beam Therapeutics: “That’s the Speculative Bottom There” - MSN

Oct 11, 2025
pulisher
Oct 11, 2025

Beam Therapeutics (NASDAQ:BEAM) Earns "Buy" Rating from HC Wainwright - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

Beam Therapeutics (NASDAQ:BEAM) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Does Beam Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals

Oct 10, 2025
pulisher
Oct 10, 2025

HC Wainwright & Co. Reiterates Beam Therapeutics (BEAM) Buy Recommendation - Nasdaq

Oct 10, 2025
pulisher
Oct 10, 2025

HC Wainwright & Co. Reiterates Buy Rating for BEAM at $80 Target - GuruFocus

Oct 10, 2025
pulisher
Oct 09, 2025

Beam Therapeutics (NASDAQ:BEAM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Beam Therapeutics Stock Soars 7.44%, Hits Intraday High of $27.55 - Markets Mojo

Oct 09, 2025
pulisher
Oct 09, 2025

Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts By Investing.com - Investing.com Canada

Oct 09, 2025
pulisher
Oct 09, 2025

Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts - Investing.com Canada

Oct 09, 2025
pulisher
Oct 09, 2025

Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts - FinancialContent

Oct 09, 2025
pulisher
Oct 09, 2025

Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target - MarketScreener

Oct 09, 2025
pulisher
Oct 09, 2025

Does Beam Therapeutics Inc. show high probability of reboundEntry Point & Step-by-Step Swing Trade Plans - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

SteelPeak Wealth LLC Invests $391,000 in Beam Therapeutics Inc. $BEAM - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Sector ETF performance correlation with Beam Therapeutics Inc.Product Launch & Low Risk Investment Opportunities - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is Beam Therapeutics Inc. stock entering bullish territoryPortfolio Update Summary & Real-Time Volume Analysis - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects - ts2.tech

Oct 08, 2025
pulisher
Oct 08, 2025

Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves - Benzinga

Oct 08, 2025
pulisher
Oct 08, 2025

What Does Wall Street Think About Beam Therapeutics (BEAM)? - MSN

Oct 08, 2025
pulisher
Oct 08, 2025

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - FinancialContent

Oct 08, 2025
pulisher
Oct 06, 2025

Using Ichimoku Cloud for Beam Therapeutics Inc. technicalsQuarterly Profit Summary & Low Risk Entry Point Tips - newser.com

Oct 06, 2025
pulisher
Oct 03, 2025

Recent Insider Transactions at Beam Therapeutics - TradingView

Oct 03, 2025
pulisher
Oct 03, 2025

Beam Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Oct 03, 2025
pulisher
Oct 01, 2025

Beam Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating - MSN

Oct 01, 2025
pulisher
Sep 29, 2025

Beam Therapeutics Inc Stock Analysis and ForecastGlobal Market Influence & Budget Friendly Capital Growth - earlytimes.in

Sep 29, 2025
pulisher
Sep 29, 2025

What analysts say about Beam Therapeutics Inc stockRelative Strength Index (RSI) & Master Timing Market Moves - earlytimes.in

Sep 29, 2025
pulisher
Sep 29, 2025

Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? - MSN

Sep 29, 2025
pulisher
Sep 28, 2025

H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum - MSN

Sep 28, 2025
pulisher
Sep 28, 2025

Is Beam Therapeutics Inc a good long term investmentGrowth vs. Value Investing & Affordable Investment Portfolio - earlytimes.in

Sep 28, 2025

Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Beam Therapeutics Inc-Aktie (BEAM) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Bellon Christine
Chief Legal Officer
Oct 01 '25
Sale
24.53
373
9,150
116,921
Evans John M.
CEO
Oct 01 '25
Option Exercise
0.67
25,000
16,750
1,011,667
Evans John M.
CEO
Oct 02 '25
Option Exercise
0.67
25,000
16,750
1,011,667
Evans John M.
CEO
Oct 02 '25
Sale
24.63
25,000
615,668
986,667
Evans John M.
CEO
Oct 01 '25
Sale
24.51
25,000
612,655
986,667
$21.75
price down icon 5.15%
$85.96
price up icon 1.45%
$32.75
price up icon 0.21%
$102.61
price up icon 0.30%
$161.38
price down icon 1.56%
biotechnology ONC
$320.94
price down icon 1.86%
Kapitalisierung:     |  Volumen (24h):